Neogen Corp (NEOG)

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Symbol
NEOG
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Devices
Market cap
$2.65B
52 week range
5.37 - 14.26

Valuation

Share price
$12.15 (close of 2026-10-02)
P/E (TTM)
-303.75x
Price to book
1.26x
Price to free cash flow
82.92x
Enterprise value
$3.25B
Book value per share
$9.61

Price performance

PeriodChange
1 day-0.74%
5 days-11.70%
1 month+2.88%
3 months+30.09%
6 months+29.12%
Year to date+73.82%
1 year+109.48%
3 years-31.20%
5 years-71.97%
10 years-42.09%
All time+2661.36%

Profitability and growth

Return on equity
-0.38%
Return on invested capital
-0.76%
Return on assets
-0.24%
Return on capital employed
-0.68%
Gross margin
46.93%
Net margin
-0.91%
EBITDA margin
10.88%
Revenue growth
-2.72%
Net income growth
99.28%
Free cash flow growth
168.75%

Cash flow and balance sheet

Free cash flow yield (TTM)
1.21%
Current ratio
3.82x
Net debt to EBITDA
3.54x

Latest reported year

Period end
2026-05-31
Fiscal year
2026
Revenue
$870.40M
Cost of revenue
$461.90M
Gross profit
$408.50M
EBITDA
$94.70M
Net income
-$7.90M
Earnings per share
$-0.04
Research and development
$18.40M
Interest expense
$24.10M
Shares outstanding
217.50M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2026-05-31$870.40M$408.50M-$7.90M$-0.04
2025-05-31$894.70M$421.40M-$1.09B$-5.03
2024-05-31$924.20M$463.90M-$9.40M$-0.04
2023-05-31$822.45M$405.95M-$22.87M$-0.12
2022-05-31$527.16M$243.01M$48.31M$0.45
2021-05-31$468.46M$215.06M$60.88M$0.57
2020-05-31$418.17M$196.28M$59.48M$0.57
2019-05-31$414.19M$191.92M$60.18M$0.58
2018-05-31$397.93M$186.27M$63.15M$0.61
2017-05-31$358.28M$168.92M$43.79M$0.43

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2026-05-3146.93%-0.91%-0.38%-0.76%
2025-05-3147.10%-122.05%-52.72%-35.96%
2024-05-3150.19%-1.02%-0.30%1.52%
2023-05-3149.36%-2.78%-0.73%0.95%
2022-05-3146.10%9.16%5.44%5.52%
2021-05-3145.91%13.00%7.24%7.79%
2020-05-3146.94%14.22%8.20%8.28%
2019-05-3146.34%14.53%9.43%9.25%
2018-05-3146.81%15.87%11.27%12.56%
2017-05-3147.15%12.22%9.28%10.72%

Cash and debt by year

Period endCashDebt
2026-05-31$185.50M$793.70M
2025-05-31$129.00M$874.80M
2024-05-31$170.61M$888.39M
2023-05-31$163.24M$885.44M
2022-05-31$44.47M-
2021-05-31$75.60M-
2020-05-31$66.27M-
2019-05-31$41.69M-
2018-05-31$83.07M-
2017-05-31$77.57M-

Free cash flow by year

Period endFree cash flowStock-based compensation
2026-05-31$31.90M$13.40M
2025-05-31-$46.40M$17.30M
2024-05-31-$76.10M$13.80M
2023-05-31-$24.73M$10.18M
2022-05-31$43.61M$7.15M
2021-05-31$54.38M$6.44M
2020-05-31$61.83M$6.47M
2019-05-31$49.18M$5.54M
2018-05-31$48.19M$4.91M
2017-05-31$45.70M$5.26M

Investor relations

Next earnings report

Next confirmed report
2026-10-06
Consensus EPS estimate
$0.04

Past earnings dates

ReportedFiscal periodEPS estimate
2026-07-30May/2026$0.03
2026-04-09Feb/2026$0.02
2026-01-08Nov/2025$0.05
2025-10-09Aug/2025$0.03
2025-07-29May/2025$0.07
2025-04-09Feb/2025$0.12
2025-01-10Nov/2024$0.11
2024-10-10Aug/2024$0.10

Filings and sources

Company website
neogen.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Abbott Laboratories (ABT) · Medtronic plc (MDT) · Stryker Corp (SYK) · Boston Scientific Corp (BSX) · Edwards Lifesciences Corp (EW) · Dexcom Inc (DXCM) · GE HealthCare Technologies Inc. (GEHC) · STERIS plc (STE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades